Progress against sarcoma

University of Utah geneticists have engineered mice that can develop synovial sarcoma a significant early step toward developing new treatments for the aggressive, deadly cancer that most often kills teenagers and young adults.

The genetically engineered, cancer-stricken mice were used to determine that synovial sarcoma develops in muscle cell precursors known as myoblasts, the researchers report in the April issue of the journal Cancer Cell, which features the study on its cover.

The cancer once was thought to arise in synovium, the membrane lining joints like the knee and elbow. That idea fell from favor in recent years, and until now, scientists have not known in which cells the cancer originated.

The only way to develop a therapy that is specific for this cancer is to understand how it works, and the mouse gives you that possibility, says the studys leader, Mario R. Capecchi, distinguished professor and co-chair of human genetics at the University of Utah School of Medicine and an investigator with the Howard Hughes Medical Institute.

But as is the case with many basic research advances, Capecchi says a treatment for synovial sarcoma based on the new finding remains at least a decade away. Nevertheless, there also is a wider promise.

First you can design and evaluate new treatments for this specific cancer and, second, you can design therapy for sarcomas in general because they share many common features with synovial sarcoma, says the studys first author, Malay Haldar, a human genetics graduate student who works in Capecchis laboratory.

Other authors of the University of Utah study are oncologist Stephen L. Lessnick, an assistant professor of pediatrics; Jeffrey D. Hancock, a fellow in pediatric hematology-oncology; and physician Cheryl Coffin, professor and head of pediatric pathology.

Broken and Fused Genes Trigger Synovial Sarcoma

Soft-tissue sarcomas are a gro

Contact: Lee Siegel
University of Utah Health Sciences Center

Page: 1 2 3 4

Related biology news :

1. Breast cancer milieu -- Progression, tamoxifen sensitivity, and DNA reversion
2. Progress toward a targeted therapy for a specific form of leukemia
3. Progress toward artificial photosynthesis?
4. 2nd annual Albert Szent-Gyrgyi Prize for Progress in Cancer Research awarded to Webster K. Cavenee
5. Progress in battle against life-threatening acute allergy
6. Progress report on Homogeneous Assay project
7. Progress being made in exploring potential use of stem cells to treat heart disease
8. Media Invite: Dinner to award prize for Progress in Cancer Research
9. Progress needed on global regime for access to genetic resources and benefit-sharing
10. Albert Szent-Gyrgyi Prize for Progress in Cancer Research announced
11. Progress toward a new remedy for chronic urinary tract infections?

Post Your Comments:

(Date:8/7/2018)... (PRWEB) , ... August 07, 2018 , ... CallTower ... today their new CT Cloud Voice and SIP solutions. CT Cloud solutions are ... secure, quality voice solution that is far superior to traditional PBX systems, at a ...
(Date:8/1/2018)... ... August 01, 2018 , ... Dr. Asher Kimchi, Founder ... winning recipients of the 2018 IAC Awards at the 23rd World Congress on Heart ... also named four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, ...
(Date:8/1/2018)... , ... August 01, 2018 , ... Visikol CEO Dr. ... services and strong pharmaceutical company partnerships that Visikol will far exceed its original 2018 ... developing its suite of digital pathology tools, whole mount imaging ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... August 08, 2018 , ... ... was developed and is continually updated by a talented scientific team that includes ... service provides: , 1. Information on the medical impact of a patient’s ...
(Date:8/9/2018)... ... August 09, 2018 , ... Simpson ... construction (AEC) experts with building owners and managers for a full-day discussion on ... Construct symposium comes to Boston for the first time on Thursday, 13 September ...
(Date:7/31/2018)... (PRWEB) , ... July 31, 2018 , ... ... 2 additional CE/IVD marked molecular quality controls to its expanding CE/IVD product inventory. ... controls to our expanding CE/IVD QC offerings. ZeptoMetrix remains entirely committed to fully ...
(Date:7/25/2018)... ... July 25, 2018 , ... Dimitrius Anagnos, an evidence-based ... combat inflammation and autoimmune disorders. , The preclinical research assessed biomarkers for ... was reported:, Over 70% decrease in Interleukin (IL-1ß) ...
Breaking Biology Technology:
Cached News: